2 days ago
Morgan Stanley met privately with Gilead Sciences (GILD) leadership at its 2026 Global Healthcare Conference this month, and the feedback strengthened the bank's positive view on the stock.
Morgan Stanley's biopharma team hosted a meeting and a management dinner with Gilead Chairman and CEO Daniel O'Day and Chief Commercial and Corporate Affairs Officer Johanna Mercier. According to a Morgan Stanley research note shared with me, the discussion reinforced its Overweight rating on Gilead and singled out one franchise as the biggest reason to stay positive.
Gilead trades around $150.89, up about 24% year to date and roughly 111% over five years. That kind of run in a biotech stock usually needs a catalyst, and Morgan Stanley points to HIV prevention. The bigger question for investors now is whether the new HIV prevention business built around Yeztugo can keep growing at the pace of the last few quarters.
Terence Flynn, a Morgan Stanley equity **** yst who covers Gilead and other healthcare stocks has held an Overweight rating on the stock since January 2025.
According to the note, Gilead management described the company as being at "an important inflection point, supported by what it views as the most robust portfolio in the company's history," with no patent expiring until 2036.
#gilead #healthcare #management #note
Morgan Stanley's biopharma team hosted a meeting and a management dinner with Gilead Chairman and CEO Daniel O'Day and Chief Commercial and Corporate Affairs Officer Johanna Mercier. According to a Morgan Stanley research note shared with me, the discussion reinforced its Overweight rating on Gilead and singled out one franchise as the biggest reason to stay positive.
Gilead trades around $150.89, up about 24% year to date and roughly 111% over five years. That kind of run in a biotech stock usually needs a catalyst, and Morgan Stanley points to HIV prevention. The bigger question for investors now is whether the new HIV prevention business built around Yeztugo can keep growing at the pace of the last few quarters.
Terence Flynn, a Morgan Stanley equity **** yst who covers Gilead and other healthcare stocks has held an Overweight rating on the stock since January 2025.
According to the note, Gilead management described the company as being at "an important inflection point, supported by what it views as the most robust portfolio in the company's history," with no patent expiring until 2036.
#gilead #healthcare #management #note
3 days ago
On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
3 days ago
Quantum computers can be better at processing data-heavy workloads in areas like science and cryptography, because they can use a concept called superposition to simulate multiple solutions to a problem at the same time. However, even the best quantum systems today are still making far too many errors to solve complex real-world problems.
Rigetti Computing (NASDAQ: RGTI) is one of the industry leaders right now, and it's making genuine progress. But considering even the company's most powerful quantum computers aren't overly useful yet, it's struggling to generate meaningful sales, so it's burning through truckloads of cash while it continues to conduct research and development.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
That creates a problem for shareholders, because Rigetti stock is trading at a sky-high valuation, which opens the door to potential downside if the company can't find a way to bring in significantly more revenue in the near future. Here's why I predict the stock will plummet over the next 12 months.
Rigetti built its own fabrication facility to produce chips, developed its own quantum programming language, and even created its own cloud platform, which it can rent to other businesses, thereby monetizing quantum computing capacity. By effectively operating its own end-to-end supply chain, the company can bring new systems to market much faster than many of its competitors.
#quantum #signal #even #company
Rigetti Computing (NASDAQ: RGTI) is one of the industry leaders right now, and it's making genuine progress. But considering even the company's most powerful quantum computers aren't overly useful yet, it's struggling to generate meaningful sales, so it's burning through truckloads of cash while it continues to conduct research and development.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
That creates a problem for shareholders, because Rigetti stock is trading at a sky-high valuation, which opens the door to potential downside if the company can't find a way to bring in significantly more revenue in the near future. Here's why I predict the stock will plummet over the next 12 months.
Rigetti built its own fabrication facility to produce chips, developed its own quantum programming language, and even created its own cloud platform, which it can rent to other businesses, thereby monetizing quantum computing capacity. By effectively operating its own end-to-end supply chain, the company can bring new systems to market much faster than many of its competitors.
#quantum #signal #even #company
3 days ago
In late 2022, OpenAI released ChatGPT, and within months the bottom rung of the tech-industry career ladder started to disappear. Graduates who majored in computer science and other AI-exposed fields are increasingly missing out on the jobs they trained for, and a chunk of them are landing behind restaurant counters and retail registers instead, according to two Census Bureau papers.
An April 2026 Census paper tracked matched employer-employee records and found that hiring of workers ages 22 to 24 fell sharply in the industries most exposed to AI, while hiring in less-exposed industries held steady. Employment for early-career workers in the most AI-exposed fifth of industries dropped 12% over the ten quarters after ChatGPT's release. Lee Tucker, one of the coauthors of the paper, said "the decline in hires is the primary cause" of that rate of unemployment, not people losing jobs they already had.
That mattered most for one type of graduate. The most AI-exposed industries, Tucker found, cluster heavily around software and information-technology work, which are the very fields computer science and other highly AI-exposed majors are built to feed into.
A second paper from last week, also coauthored by Tucker, follows the graduates of the most AI-exposed decile of college majors. Their odds of holding a job one quarter after graduation fell by five percentage points, and full-quarter initial earnings dropped 13% following ChatGPT's release. A 13% earnings decline is roughly the size economists would expect from graduating into a severe recession—except there wasn't one, since the rest of the labor market held up fine.
Young grads still need to work and still have jobs, even if they've received highly exposed degrees. So the decline in earnings is less about a lack of employment and more about pursuing lower-wage occupations to make ends meet.
#graduates
An April 2026 Census paper tracked matched employer-employee records and found that hiring of workers ages 22 to 24 fell sharply in the industries most exposed to AI, while hiring in less-exposed industries held steady. Employment for early-career workers in the most AI-exposed fifth of industries dropped 12% over the ten quarters after ChatGPT's release. Lee Tucker, one of the coauthors of the paper, said "the decline in hires is the primary cause" of that rate of unemployment, not people losing jobs they already had.
That mattered most for one type of graduate. The most AI-exposed industries, Tucker found, cluster heavily around software and information-technology work, which are the very fields computer science and other highly AI-exposed majors are built to feed into.
A second paper from last week, also coauthored by Tucker, follows the graduates of the most AI-exposed decile of college majors. Their odds of holding a job one quarter after graduation fell by five percentage points, and full-quarter initial earnings dropped 13% following ChatGPT's release. A 13% earnings decline is roughly the size economists would expect from graduating into a severe recession—except there wasn't one, since the rest of the labor market held up fine.
Young grads still need to work and still have jobs, even if they've received highly exposed degrees. So the decline in earnings is less about a lack of employment and more about pursuing lower-wage occupations to make ends meet.
#graduates
3 days ago
On Wednesday, OpenAI (OPAI.PVT) revealed six new examples of its AI models displaying "unexpected or concerning model behavior" during testing and evaluation.
The company made the announcement alongside a new framework for "tracking, reporting, and disclosing" instances where AI models take actions they otherwise aren't told to or shouldn't.
It follows a number of reports of AI models from companies hacking into third-party networks and services, including an unreleased OpenAI model breaking into the network of AI model and testing site Hugging Face.
Earlier this week, Anthropic (ANTH.PVT) CEO Dario Amodei penned a lengthy essay calling for a slowdown in the pace of the development of frontier AI models, after Anthropic researcher Jacob ******* on posted on X that he was resigning from the company because it, and his former employer OpenAI, is "racing straight to self-improving superintelligence and gambling with our lives."
Anthropic alignment science lead Evan Hubinger followed up on ******* on's comments with his own post on X saying that he believes there is a greater-than-10% chance that the technology could "kill all humans."
#face
The company made the announcement alongside a new framework for "tracking, reporting, and disclosing" instances where AI models take actions they otherwise aren't told to or shouldn't.
It follows a number of reports of AI models from companies hacking into third-party networks and services, including an unreleased OpenAI model breaking into the network of AI model and testing site Hugging Face.
Earlier this week, Anthropic (ANTH.PVT) CEO Dario Amodei penned a lengthy essay calling for a slowdown in the pace of the development of frontier AI models, after Anthropic researcher Jacob ******* on posted on X that he was resigning from the company because it, and his former employer OpenAI, is "racing straight to self-improving superintelligence and gambling with our lives."
Anthropic alignment science lead Evan Hubinger followed up on ******* on's comments with his own post on X saying that he believes there is a greater-than-10% chance that the technology could "kill all humans."
#face
4 days ago
International Business Machines (IBM) has secured a landmark $1 billion federal award from the U.S. Department of Commerce under the CHIPS and Science Act. The deal finalized non-dilutive funding to accelerate quantum wafer manufacturing at Anderon, a dedicated quantum foundry company spun out by IBM.
At the time of writing, IBM shares are down about 17% versus the start of this year.
Why It's Time to Load Up on Nvidia Stock
The Case for Selling CrowdStrike Stock
Dear Tesla Stock Fans, Mark Your Calendars for October 1
#international #commerce
At the time of writing, IBM shares are down about 17% versus the start of this year.
Why It's Time to Load Up on Nvidia Stock
The Case for Selling CrowdStrike Stock
Dear Tesla Stock Fans, Mark Your Calendars for October 1
#international #commerce
4 days ago
Danish pharmaceutical company Novo Nordisk (NVO) has teamed up with artificial intelligence (AI) leader Anthropic to leverage frontier AI models, including Claude Science, to supercharge its drug discovery and research and development (R&D) operations.
The collaboration aims to address complex biological challenges, streamline software engineering, and compress the timelines required to bring treatments for chronic diseases to market.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Why It's Time to Load Up on Nvidia Stock
The Case for Selling CrowdStrike Stock
#Stock #danish #science
The collaboration aims to address complex biological challenges, streamline software engineering, and compress the timelines required to bring treatments for chronic diseases to market.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Why It's Time to Load Up on Nvidia Stock
The Case for Selling CrowdStrike Stock
#Stock #danish #science
4 days ago
Corning Incorporated (GLW), the 175-year-old materials science giant based in Corning, New York, has become one of the more surprising beneficiaries of the artificial intelligence infrastructure buildout. Best known for its glass, ceramics, and optical technology innovations, Corning now plays a critical behind-the-scenes role as the dominant supplier of optical fiber powering hyperscale data centers and AI networks. The company has locked in major long-term supply agreements with tech heavyweights including Apple (AAPL), Meta (META), Nvidia (NVDA), Amazon (AMZN), and Verizon (VZ).
Corning stock has swung wildly of late, recently trading near $144 after plunging more than 13% in a single session following news of a $2 billion at-the-market equity offering arranged with Goldman Sachs, a move that reignited investor concerns over shareholder dilution. Shares now sit roughly in the middle of a wide 52-week range spanning $75.77 to $271.78, capturing a dramatic round trip. Corning suffered its worst monthly drop in 24 years this past July, only to rebound 8% in early September after unveiling a multibillion-dollar, 80-million-mile fiber supply deal with Verizon.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Why It's Time to Load Up on Nvidia Stock
The Case for Selling CrowdStrike Stock
#meta #fiber
Corning stock has swung wildly of late, recently trading near $144 after plunging more than 13% in a single session following news of a $2 billion at-the-market equity offering arranged with Goldman Sachs, a move that reignited investor concerns over shareholder dilution. Shares now sit roughly in the middle of a wide 52-week range spanning $75.77 to $271.78, capturing a dramatic round trip. Corning suffered its worst monthly drop in 24 years this past July, only to rebound 8% in early September after unveiling a multibillion-dollar, 80-million-mile fiber supply deal with Verizon.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Why It's Time to Load Up on Nvidia Stock
The Case for Selling CrowdStrike Stock
#meta #fiber
4 days ago
Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Insmed Incorporated (NASDAQ:INSM). The Fund exited its position in Insmed Incorporated (NASDAQ:INSM), a clinical-stage biotechnology company that develops and commercializes therapies for patients with serious and rare diseases, during the quarter. On September 15, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $119.92 per share. Over the past month, Insmed Incorporated (NASDAQ:INSM) declined 7.49%, but its shares are down 16.51% over the past year. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $26.19 billion, and its stock has traded within a 52-week range of $90.39 and $212.75.
Parnassus Growth Equity Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated (NASDAQ:INSM)shares fell after sales of the biopharmaceutical company's new lung drug Brinsupri fell short of ****** ysts' expectations. We exited the position during the quarter. Insmed's thesis had largely played out following positive TPIP data and upward revisions to Brinsupri sales. We redeployed capital to Twist Bioscience, which offers a longer runway for growth."
Insmed Incorporated (NASDAQ:INSM) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 88 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the second quarter, compared to 67 in the previous quarter. While we acknowledge the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#Growth #parnassus
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Insmed Incorporated (NASDAQ:INSM). The Fund exited its position in Insmed Incorporated (NASDAQ:INSM), a clinical-stage biotechnology company that develops and commercializes therapies for patients with serious and rare diseases, during the quarter. On September 15, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $119.92 per share. Over the past month, Insmed Incorporated (NASDAQ:INSM) declined 7.49%, but its shares are down 16.51% over the past year. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $26.19 billion, and its stock has traded within a 52-week range of $90.39 and $212.75.
Parnassus Growth Equity Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated (NASDAQ:INSM)shares fell after sales of the biopharmaceutical company's new lung drug Brinsupri fell short of ****** ysts' expectations. We exited the position during the quarter. Insmed's thesis had largely played out following positive TPIP data and upward revisions to Brinsupri sales. We redeployed capital to Twist Bioscience, which offers a longer runway for growth."
Insmed Incorporated (NASDAQ:INSM) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 88 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the second quarter, compared to 67 in the previous quarter. While we acknowledge the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#Growth #parnassus
4 days ago
Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Twist Bioscience Corporation (NASDAQ:TWST) as a new addition. Twist Bioscience Corporation (NASDAQ:TWST) is a leading biotechnology company specializing in the manufacture and sale of synthetic DNA-based products. On September 15, 2026, Twist Bioscience Corporation (NASDAQ:TWST) closed at $138.10 per share. Over the past month, Twist Bioscience Corporation (NASDAQ:TWST) returned 2.97% while its shares gained 443.64% over the past 52 weeks. Twist Bioscience Corporation (NASDAQ:TWST) has a market capitalization of $9.09 billion and its stock has traded within a 52-week range of $23.30 and $155.44.
Parnassus Growth Equity Fund stated the following regarding Twist Bioscience Corporation (NASDAQ:TWST) in its Q2 2026 investor letter:
"During the quarter, we added Twist Bioscience Corporation (NASDAQ:TWST), a biotechnology company with a proprietary silicon-based DNA synthesis platform. Twist Bioscience provides exposure to two powerful long-term trends in Health Care, AI-supported drug discovery and next-generation sequencing. The company's proprietary silicon-based DNA synthesis platform enables higher throughput and lower costs than traditional methods, creating a durable competitive advantage and positioning Twist to take share in a growing market."
Twist Bioscience Corporation (NASDAQ:TWST) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Twist Bioscience Corporation (NASDAQ:TWST) at the end of the second quarter which was 30 in the previous quarter. While we acknowledge the potential of Twist Bioscience Corporation (NASDAQ:TWST) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Twist Bioscience Corporation (NASDAQ:TWST) as a new addition. Twist Bioscience Corporation (NASDAQ:TWST) is a leading biotechnology company specializing in the manufacture and sale of synthetic DNA-based products. On September 15, 2026, Twist Bioscience Corporation (NASDAQ:TWST) closed at $138.10 per share. Over the past month, Twist Bioscience Corporation (NASDAQ:TWST) returned 2.97% while its shares gained 443.64% over the past 52 weeks. Twist Bioscience Corporation (NASDAQ:TWST) has a market capitalization of $9.09 billion and its stock has traded within a 52-week range of $23.30 and $155.44.
Parnassus Growth Equity Fund stated the following regarding Twist Bioscience Corporation (NASDAQ:TWST) in its Q2 2026 investor letter:
"During the quarter, we added Twist Bioscience Corporation (NASDAQ:TWST), a biotechnology company with a proprietary silicon-based DNA synthesis platform. Twist Bioscience provides exposure to two powerful long-term trends in Health Care, AI-supported drug discovery and next-generation sequencing. The company's proprietary silicon-based DNA synthesis platform enables higher throughput and lower costs than traditional methods, creating a durable competitive advantage and positioning Twist to take share in a growing market."
Twist Bioscience Corporation (NASDAQ:TWST) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Twist Bioscience Corporation (NASDAQ:TWST) at the end of the second quarter which was 30 in the previous quarter. While we acknowledge the potential of Twist Bioscience Corporation (NASDAQ:TWST) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands
4 days ago
Biogen Inc. (BIIB) is a global biotechnology company that develops and commercializes therapies for serious and complex diseases. Headquartered in Cambridge, Massachusetts, Biogen has built a strong presence in neurology, specialized immunology, and rare diseases, with a portfolio spanning multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, ALS, and other conditions.
Companies worth $10 billion or more are typically classified as "large-cap stocks," and Biogen, with a market cap of $32.1 billion, fits the label perfectly. Biogen's core strength lies in its deep neuroscience expertise and a portfolio of established therapies for complex neurological and rare diseases. Its long-standing research capabilities, specialized commercial infrastructure, and broad pipeline also provide scale and expertise that smaller biotech rivals can find hard to replicate.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares
#biogen #complex #expertise
Companies worth $10 billion or more are typically classified as "large-cap stocks," and Biogen, with a market cap of $32.1 billion, fits the label perfectly. Biogen's core strength lies in its deep neuroscience expertise and a portfolio of established therapies for complex neurological and rare diseases. Its long-standing research capabilities, specialized commercial infrastructure, and broad pipeline also provide scale and expertise that smaller biotech rivals can find hard to replicate.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares
#biogen #complex #expertise
4 days ago
A small, spotted tiger cat from Bolivia may just be
the beginning of a wave of new small cat species.
In 2016, Paola Nogales-Ascarrunz, a biologist and National Geographic Explorer working in Bolivia, received a call from a local wildlife sanctuary that had just been given what they described as “a weird cat.” It came from a local man who found it as a kitten on a road near a forest. The man took the animal home, believing it to be a domestic breed. But after about a year of living with the clearly wild animal, he realized it would be better off at a sanctuary.
As the lead scientist and founder of the Bolivian Felids Research Program (Programa de Investigación de Félidos Bolivia), Nogales-Ascarrunz was intrigued. The animal had a small, scrunched-up face, short and round ears, and long whiskers. It was, indeed, too small to be a housecat, and, most notably, it was covered in leopard-like spots. So she went to visit the creature at the Senda Verde wildlife sanctuary on the subtropical flank of the Bolivian Andes.
“I took a hundred pictures of it,” remembers Nogales-Ascarrunz. “I was so fascinated.”
What she couldn’t know at the time was that this curious cat had a secret. It would become the first new species of felid (i.e. the cat family) discovered in over 100 years, according to a study published today in the journal Current Biology. What’s exciting is the discovery is not a validation of a species proposed in the distant past, nor a previously recognized subspecies raised to species status—which are both more commonly reported and important findings. No, this cat was something totally new to science.
#ascarrunz #bolivian
the beginning of a wave of new small cat species.
In 2016, Paola Nogales-Ascarrunz, a biologist and National Geographic Explorer working in Bolivia, received a call from a local wildlife sanctuary that had just been given what they described as “a weird cat.” It came from a local man who found it as a kitten on a road near a forest. The man took the animal home, believing it to be a domestic breed. But after about a year of living with the clearly wild animal, he realized it would be better off at a sanctuary.
As the lead scientist and founder of the Bolivian Felids Research Program (Programa de Investigación de Félidos Bolivia), Nogales-Ascarrunz was intrigued. The animal had a small, scrunched-up face, short and round ears, and long whiskers. It was, indeed, too small to be a housecat, and, most notably, it was covered in leopard-like spots. So she went to visit the creature at the Senda Verde wildlife sanctuary on the subtropical flank of the Bolivian Andes.
“I took a hundred pictures of it,” remembers Nogales-Ascarrunz. “I was so fascinated.”
What she couldn’t know at the time was that this curious cat had a secret. It would become the first new species of felid (i.e. the cat family) discovered in over 100 years, according to a study published today in the journal Current Biology. What’s exciting is the discovery is not a validation of a species proposed in the distant past, nor a previously recognized subspecies raised to species status—which are both more commonly reported and important findings. No, this cat was something totally new to science.
#ascarrunz #bolivian
5 days ago
Updated on: September 16, 2026 / 5:45 PM EDT / CBS/AP
Scientists have discovered a crater on the moon that's bigger than the Roman Colosseum and is the result of a powerful impact two years ago that initially went undetected.
The steep-sided hole measured about 728 feet across, the length of two football fields, and up to 141 feet deep, equivalent to three vertically stacked yellow school buses, according to NASA. It's the solar system's biggest known impact crater carved out in recent times.
Such a large-scale event is estimated to occur only once every 132 years, researchers said, making this a treasure trove of information as NASA prepares to build a base for astronauts on the moon.
"This event constitutes a statistically rare, effectively once-in-a-lifetime observation," the scientists wrote in one of two studies appearing on the subject Wednesday in the journal Science Advances.
#crater
Scientists have discovered a crater on the moon that's bigger than the Roman Colosseum and is the result of a powerful impact two years ago that initially went undetected.
The steep-sided hole measured about 728 feet across, the length of two football fields, and up to 141 feet deep, equivalent to three vertically stacked yellow school buses, according to NASA. It's the solar system's biggest known impact crater carved out in recent times.
Such a large-scale event is estimated to occur only once every 132 years, researchers said, making this a treasure trove of information as NASA prepares to build a base for astronauts on the moon.
"This event constitutes a statistically rare, effectively once-in-a-lifetime observation," the scientists wrote in one of two studies appearing on the subject Wednesday in the journal Science Advances.
#crater
5 days ago
Agriscience business Corteva (CTVA) is gearing up to spin off its seed operating segment as an independently traded public company, Vylor, trading under the "VYLR" ticker. Shareholders have already approved the separation, and they are expected to receive one Vylor common share for each Corteva common share they hold. VYLR is set to begin trading on Oct. 1. The company is holding an Investor Day webcast on Sept. 15.
Corteva believes this spinoff will give both companies more flexibility. However, ****** ysts have questioned whether it weakens the entities. Meanwhile, CEO Luke Kissam has highlighted a pipeline Corteva values at $11 billion through 2040 and its plan to introduce 12 products over the next decade. Contrarily, competition from generic products remains, and President Donald Trump's administration is exploring whether consolidation among agricultural suppliers has driven up input costs.
Goldman Sachs Expects Fed Chair Kevin Warsh to Raise Rates This Week — But Not Because of Oil Prices.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Morgan Stanley Doubles Down on Apple Stock as New Offerings Become 'More Exciting'
#corteva
Corteva believes this spinoff will give both companies more flexibility. However, ****** ysts have questioned whether it weakens the entities. Meanwhile, CEO Luke Kissam has highlighted a pipeline Corteva values at $11 billion through 2040 and its plan to introduce 12 products over the next decade. Contrarily, competition from generic products remains, and President Donald Trump's administration is exploring whether consolidation among agricultural suppliers has driven up input costs.
Goldman Sachs Expects Fed Chair Kevin Warsh to Raise Rates This Week — But Not Because of Oil Prices.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Morgan Stanley Doubles Down on Apple Stock as New Offerings Become 'More Exciting'
#corteva
5 days ago
Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of ***** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.
#billion #depuy
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of ***** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.
#billion #depuy
5 days ago
Broyhill **** et Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index's 15.1% and the MSCI ACWI Value Index's 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The letter highlights that a significant portion of the shortfall occurred in April due to market dynamics and geopolitical events, with tech, particularly semiconductors, driving recent gains. Broyhill notes its lack of direct semiconductor exposure but acknowledges potential interest in the sector if opportunities arise, maintaining its investment philosophy focused on capital protection in fragile market conditions. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Broyhill **** et Management highlighted IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is a US-based provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. On September 14, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed at $265.67 per share. Over the past month, IQVIA Holdings Inc. (NYSE:IQV) returned 10.68%, and its shares are up 42.21% over the past year. IQVIA Holdings Inc. (NYSE:IQV) has a market capitalization of $43.73 billion, and its stock has traded within a 52-week range of $154.50 to $271.80.
Broyhill **** et Management stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q2 2026 investor letter:
"IQVIA Holdings Inc. (NYSE:IQV) gained 14% after being our largest detractor in the first quarter. We set out our full case last quarter and will not repeat it here. The second quarter added evidence: results came in ahead, and request-for-proposal flow and award timing both improved. We trimmed the position in June and rolled the proceeds into Thermo Fisher, an exercise in portfolio management rather than a statement about our conviction."
IQVIA Holdings Inc. (NYSE:IQV) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the second quarter, down from 64 in the previous quarter. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#iqvia
In its second-quarter 2026 investor letter, Broyhill **** et Management highlighted IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is a US-based provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. On September 14, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed at $265.67 per share. Over the past month, IQVIA Holdings Inc. (NYSE:IQV) returned 10.68%, and its shares are up 42.21% over the past year. IQVIA Holdings Inc. (NYSE:IQV) has a market capitalization of $43.73 billion, and its stock has traded within a 52-week range of $154.50 to $271.80.
Broyhill **** et Management stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q2 2026 investor letter:
"IQVIA Holdings Inc. (NYSE:IQV) gained 14% after being our largest detractor in the first quarter. We set out our full case last quarter and will not repeat it here. The second quarter added evidence: results came in ahead, and request-for-proposal flow and award timing both improved. We trimmed the position in June and rolled the proceeds into Thermo Fisher, an exercise in portfolio management rather than a statement about our conviction."
IQVIA Holdings Inc. (NYSE:IQV) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the second quarter, down from 64 in the previous quarter. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#iqvia
5 days ago
Wednesday’s Senate confirmation hearing wasn’t the first time much of the American public met Dr. Nicole Saphier and heard her perspective; President Donald Trump’s nominee for US surgeon general is a health and wellness influencer who has amassed hundreds of thousands of followers through her podcast and social media platforms.
In some ways, the surgeon general position – often referred to as the nation’s doctor – is the original health influencer, tasked with translating science into terms that are easy to understand and guiding the public on ways to improve their health.
“For a decade, I have specialized in translating complex, fast-evolving medical information on various media platforms into content that millions of Americans can understand and use, including during the uncertainty of the global pandemic,” Saphier, a radiologist and Fox News contributor, said in Wednesday’s hearing.
“I realized then how badly this country needs public health communication that is straightforward and grounded in the best evidence available,” she said. “My years of communicating directly with the public have prepared me to explain complex topics in a way that they can understand.”
But experts say that social media has changed how people receive health information, with increasingly blurred lines as to who is considered to have authority and expertise – and that bringing an influencer into the role of surgeon general presents both opportunities and challenges.
#public #saphier #hearing
In some ways, the surgeon general position – often referred to as the nation’s doctor – is the original health influencer, tasked with translating science into terms that are easy to understand and guiding the public on ways to improve their health.
“For a decade, I have specialized in translating complex, fast-evolving medical information on various media platforms into content that millions of Americans can understand and use, including during the uncertainty of the global pandemic,” Saphier, a radiologist and Fox News contributor, said in Wednesday’s hearing.
“I realized then how badly this country needs public health communication that is straightforward and grounded in the best evidence available,” she said. “My years of communicating directly with the public have prepared me to explain complex topics in a way that they can understand.”
But experts say that social media has changed how people receive health information, with increasingly blurred lines as to who is considered to have authority and expertise – and that bringing an influencer into the role of surgeon general presents both opportunities and challenges.
#public #saphier #hearing
5 days ago
Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of **** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.
#NYSE #johnson
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of **** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.
#NYSE #johnson
5 days ago
Broyhill **** et Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index's 15.1% and the MSCI ACWI Value Index's 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The letter highlights that a significant portion of the shortfall occurred in April due to market dynamics and geopolitical events, with tech, particularly semiconductors, driving recent gains. Broyhill notes its lack of direct semiconductor exposure but acknowledges potential interest in the sector if opportunities arise, maintaining its investment philosophy focused on capital protection in fragile market conditions. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Broyhill **** et Management highlighted IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is a US-based provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. On September 14, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed at $265.67 per share. Over the past month, IQVIA Holdings Inc. (NYSE:IQV) returned 10.68%, and its shares are up 42.21% over the past year. IQVIA Holdings Inc. (NYSE:IQV) has a market capitalization of $43.73 billion, and its stock has traded within a 52-week range of $154.50 to $271.80.
Broyhill **** et Management stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q2 2026 investor letter:
"IQVIA Holdings Inc. (NYSE:IQV) gained 14% after being our largest detractor in the first quarter. We set out our full case last quarter and will not repeat it here. The second quarter added evidence: results came in ahead, and request-for-proposal flow and award timing both improved. We trimmed the position in June and rolled the proceeds into Thermo Fisher, an exercise in portfolio management rather than a statement about our conviction."
IQVIA Holdings Inc. (NYSE:IQV) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the second quarter, down from 64 in the previous quarter. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#holdings #letter #investor
In its second-quarter 2026 investor letter, Broyhill **** et Management highlighted IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is a US-based provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. On September 14, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed at $265.67 per share. Over the past month, IQVIA Holdings Inc. (NYSE:IQV) returned 10.68%, and its shares are up 42.21% over the past year. IQVIA Holdings Inc. (NYSE:IQV) has a market capitalization of $43.73 billion, and its stock has traded within a 52-week range of $154.50 to $271.80.
Broyhill **** et Management stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q2 2026 investor letter:
"IQVIA Holdings Inc. (NYSE:IQV) gained 14% after being our largest detractor in the first quarter. We set out our full case last quarter and will not repeat it here. The second quarter added evidence: results came in ahead, and request-for-proposal flow and award timing both improved. We trimmed the position in June and rolled the proceeds into Thermo Fisher, an exercise in portfolio management rather than a statement about our conviction."
IQVIA Holdings Inc. (NYSE:IQV) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the second quarter, down from 64 in the previous quarter. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#holdings #letter #investor
6 days ago
Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Insmed Incorporated (NASDAQ:INSM). The Fund exited its position in Insmed Incorporated (NASDAQ:INSM), a clinical-stage biotechnology company that develops and commercializes therapies for patients with serious and rare diseases, during the quarter. On September 15, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $119.92 per share. Over the past month, Insmed Incorporated (NASDAQ:INSM) declined 7.49%, but its shares are down 16.51% over the past year. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $26.19 billion, and its stock has traded within a 52-week range of $90.39 and $212.75.
Parnassus Growth Equity Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated (NASDAQ:INSM)shares fell after sales of the biopharmaceutical company's new lung drug Brinsupri fell short of ******* ysts' expectations. We exited the position during the quarter. Insmed's thesis had largely played out following positive TPIP data and upward revisions to Brinsupri sales. We redeployed capital to Twist Bioscience, which offers a longer runway for growth."
Insmed Incorporated (NASDAQ:INSM) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 88 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the second quarter, compared to 67 in the previous quarter. While we acknowledge the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#Growth
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Insmed Incorporated (NASDAQ:INSM). The Fund exited its position in Insmed Incorporated (NASDAQ:INSM), a clinical-stage biotechnology company that develops and commercializes therapies for patients with serious and rare diseases, during the quarter. On September 15, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $119.92 per share. Over the past month, Insmed Incorporated (NASDAQ:INSM) declined 7.49%, but its shares are down 16.51% over the past year. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $26.19 billion, and its stock has traded within a 52-week range of $90.39 and $212.75.
Parnassus Growth Equity Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated (NASDAQ:INSM)shares fell after sales of the biopharmaceutical company's new lung drug Brinsupri fell short of ******* ysts' expectations. We exited the position during the quarter. Insmed's thesis had largely played out following positive TPIP data and upward revisions to Brinsupri sales. We redeployed capital to Twist Bioscience, which offers a longer runway for growth."
Insmed Incorporated (NASDAQ:INSM) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 88 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the second quarter, compared to 67 in the previous quarter. While we acknowledge the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#Growth
6 days ago
Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Twist Bioscience Corporation (NASDAQ:TWST) as a new addition. Twist Bioscience Corporation (NASDAQ:TWST) is a leading biotechnology company specializing in the manufacture and sale of synthetic DNA-based products. On September 15, 2026, Twist Bioscience Corporation (NASDAQ:TWST) closed at $138.10 per share. Over the past month, Twist Bioscience Corporation (NASDAQ:TWST) returned 2.97% while its shares gained 443.64% over the past 52 weeks. Twist Bioscience Corporation (NASDAQ:TWST) has a market capitalization of $9.09 billion and its stock has traded within a 52-week range of $23.30 and $155.44.
Parnassus Growth Equity Fund stated the following regarding Twist Bioscience Corporation (NASDAQ:TWST) in its Q2 2026 investor letter:
"During the quarter, we added Twist Bioscience Corporation (NASDAQ:TWST), a biotechnology company with a proprietary silicon-based DNA synthesis platform. Twist Bioscience provides exposure to two powerful long-term trends in Health Care, AI-supported drug discovery and next-generation sequencing. The company's proprietary silicon-based DNA synthesis platform enables higher throughput and lower costs than traditional methods, creating a durable competitive advantage and positioning Twist to take share in a growing market."
Twist Bioscience Corporation (NASDAQ:TWST) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Twist Bioscience Corporation (NASDAQ:TWST) at the end of the second quarter which was 30 in the previous quarter. While we acknowledge the potential of Twist Bioscience Corporation (NASDAQ:TWST) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Twist Bioscience Corporation (NASDAQ:TWST) as a new addition. Twist Bioscience Corporation (NASDAQ:TWST) is a leading biotechnology company specializing in the manufacture and sale of synthetic DNA-based products. On September 15, 2026, Twist Bioscience Corporation (NASDAQ:TWST) closed at $138.10 per share. Over the past month, Twist Bioscience Corporation (NASDAQ:TWST) returned 2.97% while its shares gained 443.64% over the past 52 weeks. Twist Bioscience Corporation (NASDAQ:TWST) has a market capitalization of $9.09 billion and its stock has traded within a 52-week range of $23.30 and $155.44.
Parnassus Growth Equity Fund stated the following regarding Twist Bioscience Corporation (NASDAQ:TWST) in its Q2 2026 investor letter:
"During the quarter, we added Twist Bioscience Corporation (NASDAQ:TWST), a biotechnology company with a proprietary silicon-based DNA synthesis platform. Twist Bioscience provides exposure to two powerful long-term trends in Health Care, AI-supported drug discovery and next-generation sequencing. The company's proprietary silicon-based DNA synthesis platform enables higher throughput and lower costs than traditional methods, creating a durable competitive advantage and positioning Twist to take share in a growing market."
Twist Bioscience Corporation (NASDAQ:TWST) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Twist Bioscience Corporation (NASDAQ:TWST) at the end of the second quarter which was 30 in the previous quarter. While we acknowledge the potential of Twist Bioscience Corporation (NASDAQ:TWST) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands
8 days ago
NEW YORK (AP) — Bob Mackie, the fashion designer whose visually provocative Hollywood style defined glamour for the 1970s — including putting Carol Burnett in some of her kookiest getups and Cher in her raciest ones — died Monday. He was 87.
"He lived his 87 years to the fullest, fulfilling his dream of being a Fashion and Costume Designer, which is all he ever wanted to do," a read statement on his social media accounts. "His genius and extraordinary designs will live on forever, continuing to bring beauty into this world."
Dubbed the "Designer to the Stars," Mackie won nine Emmy Awards, a Tony Award and was nominated for three Oscars, including one for Barbra Streisand's "Funny Lady," in which she wore a sheer batwing gown. He was inducted into the Academy of Television Arts & Science's Hall of Fame in 2002.
He designed gowns for Madonna, Barbra Streisand, Sharon Stone, Diana Ross and Julia Louis-Dreyfus, and concert costumes for Pink. When Marilyn Monroe delivered a breathy, seductive take on "Happy Birthday" at a fundraiser for President John F. Kennedy and the Democratic National Committee, she did it in a sheer, beaded gown that Mackie dreamed up in a sketch.
His influence can be seen in the styles of Kendall Jenner and Bella Hadid. His archival pieces are worn today by the likes of Anya Taylor-Joy, Miley Cyrus and Zendaya, the latter who wore a Mackie gown to honor Cher at the 2024 Rock & Roll Hall of Fame induction ceremony. When Taylor Swift wanted to look like a showgirl on the cover of her 2025 album "The Life of a Showgirl," she turned to some Mackie originals.
#fame #fashion #showgirl
"He lived his 87 years to the fullest, fulfilling his dream of being a Fashion and Costume Designer, which is all he ever wanted to do," a read statement on his social media accounts. "His genius and extraordinary designs will live on forever, continuing to bring beauty into this world."
Dubbed the "Designer to the Stars," Mackie won nine Emmy Awards, a Tony Award and was nominated for three Oscars, including one for Barbra Streisand's "Funny Lady," in which she wore a sheer batwing gown. He was inducted into the Academy of Television Arts & Science's Hall of Fame in 2002.
He designed gowns for Madonna, Barbra Streisand, Sharon Stone, Diana Ross and Julia Louis-Dreyfus, and concert costumes for Pink. When Marilyn Monroe delivered a breathy, seductive take on "Happy Birthday" at a fundraiser for President John F. Kennedy and the Democratic National Committee, she did it in a sheer, beaded gown that Mackie dreamed up in a sketch.
His influence can be seen in the styles of Kendall Jenner and Bella Hadid. His archival pieces are worn today by the likes of Anya Taylor-Joy, Miley Cyrus and Zendaya, the latter who wore a Mackie gown to honor Cher at the 2024 Rock & Roll Hall of Fame induction ceremony. When Taylor Swift wanted to look like a showgirl on the cover of her 2025 album "The Life of a Showgirl," she turned to some Mackie originals.
#fame #fashion #showgirl
8 days ago
Tech stocks fell on Monday, as AI industry leaders raised concerns about the future of the technology and its potential to harm humans. The Nasdaq fell roughly 0.8% in early trading. The Philadelphia Semiconductor Index fell more than 4%.
The episode began last week when an Anthropic researcher announced he was leaving the company via a post on X, saying he didn't feel it was doing enough to keep AI in check.
Anthropic Alignment Science Lead, Evan Hubinger, responded the post saying the former Anthropic worker is correct and that he believes there is a greater-than-10 % chance that the technology could "kill all humans."
On Saturday, Anthropic CEO Dario Amodei posted an essay responding to the posts, calling on AI companies to slow the pace of frontier AI development. OpenAI CEO Sam Altman agreed.
And on Monday, Reuters reported that Microsoft is developing its own code of conduct for its AI models.
#anthropic #Monday #Tech
The episode began last week when an Anthropic researcher announced he was leaving the company via a post on X, saying he didn't feel it was doing enough to keep AI in check.
Anthropic Alignment Science Lead, Evan Hubinger, responded the post saying the former Anthropic worker is correct and that he believes there is a greater-than-10 % chance that the technology could "kill all humans."
On Saturday, Anthropic CEO Dario Amodei posted an essay responding to the posts, calling on AI companies to slow the pace of frontier AI development. OpenAI CEO Sam Altman agreed.
And on Monday, Reuters reported that Microsoft is developing its own code of conduct for its AI models.
#anthropic #Monday #Tech
9 days ago
On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead's HIV medication for the US market and the foreign versions being imported were "material, not theoretical." The controversy began in December 2024 when Gilead Sciences, Inc. (NASDAQ:GILD) filed suit against a number of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its best-selling HIV drug Biktarvy.
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
#gild
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
#gild
10 days ago
Horizon Technology Finance Corp., an affiliate of Monroe Capital, on September 10 said that the RoHo Capital Opportunity Fund LLC, a joint venture formed by Horizon and CR Financial Holdings, Inc., the holding company for Roth Capital Partners, LLC, has provided a $20-million senior credit facility to NeoVolta, Inc., with the ability to increase the facility to $30 million upon mutual agreement. An initial $20 million was funded at closing to support NeoVolta's continued growth.NeoVolta is an energy technology company focused on developing and manufacturing domestic battery energy storage systems (BESS). Together with its joint venture partner LONGi, NeoVolta is developing a 210,600-square-foot manufacturing facility in Pendergrass, Georgia, to produce BESS systems designed to meet U.S. domestic content and supply-chain requirements. The facility is expected to have an initial annual production capacity of up to 2 GWh, with the potential to scale to 8 GWh over time."Providing growth capital to innovative companies operating in attractive, high-growth markets is a core focus of RoHo's investment strategy," said Paul Seitz, chief investment officer of Horizon. "Formed by Horizon and Roth Capital, RoHo pairs Horizon's venture lending and structuring expertise with Roth's deep public markets relationships to deliver flexible growth capital to small- and micro-cap public companies. We are pleased to support NeoVolta's growth plans with a tailored financing solution and look forward to continuing to deploy capital through RoHo in support of innovative public companies pursuing significant market opportunities.""Horizon and Roth Capital bring valuable experience and a collaborative approach as we advance NeoVolta's domestic battery energy storage systems manufacturing platform," said Ardes Johnson, CEO of NeoVolta. "As we ramp our Georgia facility and pursue larger commercial and utility-scale opportunities, this relationship supports our ability to execute on our long-term growth strategy."Horizon Technology Finance Corp. is a specialty finance company that provides capital in the form of secured loans to venture capital and private equity-backed companies and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S.Monroe Capital is a premier ****** et management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity.CR Financial Holdings, Inc., is a private hol
10 days ago
Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $42.3 billion by market cap, the company offers ******* ytics, technology solutions, and clinical research services to the life sciences industry which helps them in the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.
Companies worth $10 billion or more are generally described as "large-cap stocks," and IQV perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. With strong revenue growth and a global presence in over 100 countries, IQVIA's expertise and scale provide a competitive edge that is hard to replicate.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e
#Research #Stock #healthcare
Companies worth $10 billion or more are generally described as "large-cap stocks," and IQV perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. With strong revenue growth and a global presence in over 100 countries, IQVIA's expertise and scale provide a competitive edge that is hard to replicate.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e
#Research #Stock #healthcare
10 days ago
Based in Midland, Michigan, Dow Inc. (DOW) is a global materials science leader that develops and manufactures chemicals, plastics, coatings, silicones, and other advanced materials used across industries ranging from packaging and construction to automotive, electronics, and consumer products.
Companies valued between $10 billion and $200 billion are typically classified as "large-cap stocks," and DOW, with a market capitalization of $21.4 billion, fits the label perfectly. Its key competitive advantage is its global scale, deep materials-science expertise, and broad portfolio of essential chemicals and advanced materials.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e
#billion #science
Companies valued between $10 billion and $200 billion are typically classified as "large-cap stocks," and DOW, with a market capitalization of $21.4 billion, fits the label perfectly. Its key competitive advantage is its global scale, deep materials-science expertise, and broad portfolio of essential chemicals and advanced materials.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e
#billion #science
11 days ago
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its bispecific T-cell engager, etentamig, in relapsed/refractory multiple myeloma. Together, the dual catalysts emphasize how mega-cap pharmaceutical giants are deploying cash flow from legacy franchises to lock in next-generation immunology and oncology ***** ets.
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.
#phase #revenue #Growth
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.
#phase #revenue #Growth
11 days ago
Interested in AbbVie Inc.? Here are five stocks we like better.
SKYRIZI and RINVOQ remain AbbVie's main growth drivers, with additional opportunities in inflammatory bowel disease, vitiligo, alopecia and hidradenitis suppurativa. The company expects a subcutaneous SKYRIZI induction approval for Crohn's disease in the fourth quarter and plans further combination-therapy data.
AbbVie is advancing a broad pipeline, including the BCMA-directed cancer therapy etentamig, which showed strong early multiple-myeloma results and could support a rapid regulatory filing. Neuroscience programs such as bretisilocin for depression are also expected to deliver additional data this year.
The company is taking a selective approach to acquisitions and partnerships, having invested about $20 billion in roughly 30 transactions while increasing annual R&D spending toward $10 billion. Management maintained its outlook for high-single-digit annual revenue growth through the decade.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
#disease #company #Therapy
SKYRIZI and RINVOQ remain AbbVie's main growth drivers, with additional opportunities in inflammatory bowel disease, vitiligo, alopecia and hidradenitis suppurativa. The company expects a subcutaneous SKYRIZI induction approval for Crohn's disease in the fourth quarter and plans further combination-therapy data.
AbbVie is advancing a broad pipeline, including the BCMA-directed cancer therapy etentamig, which showed strong early multiple-myeloma results and could support a rapid regulatory filing. Neuroscience programs such as bretisilocin for depression are also expected to deliver additional data this year.
The company is taking a selective approach to acquisitions and partnerships, having invested about $20 billion in roughly 30 transactions while increasing annual R&D spending toward $10 billion. Management maintained its outlook for high-single-digit annual revenue growth through the decade.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
#disease #company #Therapy
11 days ago
It looks like the American consumer has more to worry about than food recalls and cyclospora—a new study found that even the packaging the food comes in may pose some health concerns.
Out of over 15,000 food contact chemicals (FCCs), 1,222 or 8% can pose serious health risks, according to a recent study published in the peer-reviewed journal Environmental Science & Technology. Some of these FCCs, which in general are "substances that come into contact with food, such as through food packaging, processing, storage or other handling," per the FDA, were found to be hazardous to human health.
Researchers from the nonprofit Food Packaging Forum Foundation, which conducted the study, found at least 2,160 chemicals regularly contact food and "migrate into foodstuffs." Using guidelines from the UN's Globally Harmonized System of Classification and Labeling of Chemicals (GHS), researchers found some of the chemicals related to food packaging and other materials were "carcinogenic, mutagenic, toxic to reproduction, harmful to specific organs after repeated exposure, [and] endocrine disrupting."
That's not the only concerning part. The researchers found that 13,211 of the 15,159 known food-contact chemicals lacked harmonized hazard data. That means the scientists could not determine from the available data whether those chemicals met the study's criteria for being hazardous.
"There's a lot of ways of establishing whether something is hazardous or not, and some methods are based very much just on computer models, looking at the structure, predicting something. And others are based on in vitro tests," Dr. Helene Wiesinger, scientific communication officer at the nonprofit and one of the researchers on the study, told Fortune. "And in some sense, the data that we used?' So this is the data we used, and the problem we ran into at that point was that there were huge data lags."
#Food #study #contact
Out of over 15,000 food contact chemicals (FCCs), 1,222 or 8% can pose serious health risks, according to a recent study published in the peer-reviewed journal Environmental Science & Technology. Some of these FCCs, which in general are "substances that come into contact with food, such as through food packaging, processing, storage or other handling," per the FDA, were found to be hazardous to human health.
Researchers from the nonprofit Food Packaging Forum Foundation, which conducted the study, found at least 2,160 chemicals regularly contact food and "migrate into foodstuffs." Using guidelines from the UN's Globally Harmonized System of Classification and Labeling of Chemicals (GHS), researchers found some of the chemicals related to food packaging and other materials were "carcinogenic, mutagenic, toxic to reproduction, harmful to specific organs after repeated exposure, [and] endocrine disrupting."
That's not the only concerning part. The researchers found that 13,211 of the 15,159 known food-contact chemicals lacked harmonized hazard data. That means the scientists could not determine from the available data whether those chemicals met the study's criteria for being hazardous.
"There's a lot of ways of establishing whether something is hazardous or not, and some methods are based very much just on computer models, looking at the structure, predicting something. And others are based on in vitro tests," Dr. Helene Wiesinger, scientific communication officer at the nonprofit and one of the researchers on the study, told Fortune. "And in some sense, the data that we used?' So this is the data we used, and the problem we ran into at that point was that there were huge data lags."
#Food #study #contact
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
